Elanco Animal Health

ELAN

Market cap $9.26B

Overview Fund Activity

18.64 USD

+0.21

1.14%

At close Updated Sep 18, 9:54 AM EDT

1 day

1.14%

5 days

-0.27%

1 month

5.31%

3 months

39.83%

6 months

72.43%

Year to date

54.69%

1 year

27.24%

5 years

-29.77%

10 years

-48.22%

About: Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.

Employees: 9,450

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 4 (+2) [Q2]

48% more capital invested

Capital invested by funds: $5.19B [Q1] → $7.69B (+$2.5B) [Q2]

16% more first-time investments, than exits

New positions opened: 59 | Existing positions closed: 51

8.52% more ownership

Funds ownership: 99.87% [Q1] → 108.4% (+8.52%) [Q2]

1% more funds holding

Funds holding: 358 [Q1] → 362 (+4) [Q2]

1% more repeat investments, than reductions

Existing positions increased: 129 | Existing positions reduced: 128

24% less call options, than puts

Call options by funds: $17.4M | Put options by funds: $23.1M

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$17

9% downside

Avg. target

$18

3% downside

High target

$19

2% upside

4 analyst ratings

3 positive

75%

1 neutral

25%

0 negative

0%

Piper Sandler David Westenberg	$18	Neutral Maintained	11 Aug 2025
UBS Andrea Alfonso	$19	Buy Maintained	8 Aug 2025
Leerink Partners Daniel Clark	$18	Outperform Upgraded	17 Jul 2025
Stifel Jonathan Block	$17	Buy Maintained	2 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about ELAN published over the past 30 days

Elanco Animal Health Incorporated (ELAN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Elanco Animal Health Incorporated (NYSE:ELAN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 8:30 AM EDT Company Participants Jeffrey Simmons - President, CEO & Director Robert VanHimbergen - Executive VP & CFO Conference Call Participants Erin Wilson Wright - Morgan Stanley, Research Division Presentation Erin Wilson Wright Equity Analyst Hi. Good morning, everyone.

Elanco Animal Health Incorporated (ELAN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Elanco Innovation Builds Momentum, Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Reaches Blockbuster Status

Credelio Quattro marked $100 million in net sales making it Elanco's fastest pet health blockbuster in history and one of the industry's fastest ever, especially with a single geographic approval Credelio Quattro joins Experior® as Elanco's second of six recently launched blockbuster-potential products to reach the $100 million annual net sales milestone Zenrelia™ (ilunocitinib tablets) now in market in the European Union (EU) and Great Britain GREENFIELD, Ind. , Sept. 8, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) has announced significant advancements with its two most recent pet health innovations—Credelio Quattro and Zenrelia—further demonstrating the company's commitment to helping pet owners and veterinarians around the world go beyond today's standard of treatment.

Elanco Innovation Builds Momentum, Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Reaches Blockbuster Status

Splenda® Joins Elanco and HATCH to Support 'Nutrition Secure Indianapolis' to Strengthen Family Health Through Nutrition and Education

Coalition of community leaders creates new initiative that delivers weekly nutritious food, sugar reduction tools, and wellness education to 250 families across Indianapolis CARMEL, Ind. , Aug. 27, 2025 /PRNewswire/ -- Splenda®, a leading global health and wellness brand in sweeteners, has teamed up with Elanco and HATCH, as well as other partners to sponsor Nutrition Secure Indianapolis, a first-of-its-kind program addressing food insecurity and promoting proper nutrition by delivering weekly nutritious food boxes and holistic nutrition support to families across Indianapolis.

Splenda® Joins Elanco and HATCH to Support 'Nutrition Secure Indianapolis' to Strengthen Family Health Through Nutrition and Education

Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600

NEW YORK , Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE: ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (XNYS: BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions.

Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600

Elanco to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference

GREENFIELD, Ind. , Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 23rd Annual Global Healthcare Conference, September 8-9, 2025.

Elanco to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference

Elanco Animal Health Incorporated (ELAN) Q2 2025 Earnings Call Transcript

Elanco Animal Health Incorporated (NYSE:ELAN ) Q2 2025 Earnings Conference Call August 7, 2025 9:00 AM ET Company Participants Jeffrey N. Simmons - President, CEO & Director Robert M.

Elanco Animal Health Incorporated (ELAN) Q2 2025 Earnings Call Transcript

Elanco Animal Health Q2: Rising Innovation Revenue, Initiate At Buy

I rate Elanco Animal Health Incorporated shares a Buy with a $20 fair value, driven by strong innovation and recent operational improvements. Elanco's focus on innovative products like Zenrelia and strategic divestitures positions it for growth in both companion and farm animal markets. Strong Q2 results, raised full-year guidance, and increased innovation revenue targets support my positive outlook for future growth.

Elanco Animal Health Q2: Rising Innovation Revenue, Initiate At Buy

Elanco Animal Health Soars Past 52-Week High On Strong Sales, Raised Annual Outlook

Elanco Animal Health Incorporated ELAN reported second-quarter 2025 results on Thursday, posting adjusted earnings per share of 26 cents, down 13% year over year.

Elanco Animal Health Soars Past 52-Week High On Strong Sales, Raised Annual Outlook

Zacks Investment Research

Elanco Animal Health (ELAN) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Elanco Animal Health (ELAN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Elanco Animal Health (ELAN) Reports Q2 Earnings: What Key Metrics Have to Say

Zacks Investment Research

Elanco Animal Health Incorporated (ELAN) Q2 Earnings and Revenues Beat Estimates

Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to earnings of $0.3 per share a year ago.

Elanco Animal Health Incorporated (ELAN) Q2 Earnings and Revenues Beat Estimates

See News Rankings

Charts implemented using Lightweight Charts™